Lysogene is a global leader in the basic research and clinical development of gene therapy for neurodegenerative disorders.

Our mission is to radically improve the health of patients suffering from incurable life threatening conditions. We do this by developing AAV vectors that have demonstrated their effectiveness in safely delivering genetic material to the central nervous system.

In the clinic

MPS IIIA

Lysogene successfully completed its phase I/II clinical trial of gene therapy in MPS IIIA and plans its phase II/III registrational trials ... Read More


GM1 Gangliosidosis

Lysogene develops IND-supporting preclinical studies and plans its phase I/II clinical trial of gene therapy in GM1 gangliosidosis ... Read More

Latest tweet

Get in touch

Follow us

Join our mailing list